Artificial Insemination Market Size Worth $2.63 Billion by 2025: Grand View Research, Inc.
SAN FRANCISCO, June 21, 2018 /PRNewswire/ --
The global artificial insemination market is expected to reach USD 2.63 billion by 2025, according to a new report by Grand View Research, Inc. Over the past few years, infertility has become a major public health concern across the globe. Artificial insemination is usually the preferred first-line treatment for infertility. According to WHO, around 10% of women in the world are struggling to get pregnant. Lifestyle changes, delay in pregnancy, and hormonal issues are some of the reasons contributing to the rise in infertility around the world.
The exact estimation of infertility statistics is challenging, however, WHO monitors its prevalence across the world. At present, 46% of the global population lives in countries having low levels of fertility. According to United Nations, the global rate of fertility is expected to decline to 2.4 by 2030 and 2.2 by 2050. In developing or underdeveloped nations, medical consultation regarding infertility and childlessness was not easily accessible. Hence, there was lack of awareness about available assisted reproductive techniques including artificial or donor insemination and IVF
Artificial insemination is a first-line infertility treatment as it is minimally invasive and less expensive as compared to IVF
It is preferred mostly by single women who wish to conceive and same-sex partners with the help of fresh or frozen donor sperm samples. In some countries, lesbian couples are provided insurance coverage for these procedures
Intrauterine Insemination (IUI) held majority of the market share in 2017 and is likely to be the fastest-growing segment over the forecast period, as it is the most common and noninvasive procedure.
Fertility clinics held majority of the market share in 2017 as the number of medical facilities offering infertility treatments has been increasing over the past decade
Fertility clinics provide medical consultation regarding the detection of ovulation to perform the procedure for insemination. Sperm washing is also performed in the clinics to achieve optimum results
Artificial insemination with partner's or (AIH) sample held the majority of the source type segment share
Europe held majority of the market share in 2017 due to the presence of the largest number of patients and easily accessible treatment options
On the other hand, Asia Pacific is expected to be the fastest-growing regional market due to increase in awareness regarding artificial or donor insemination in the region
Some of the key players in this market include Irvine Scientific; Rinovum Women's Health, LLC; TenderNeeds Fertility; Conceivex, Inc.; Hi-Tech Solutions; among others.
Grand View Research has segmented the Artificial Insemination market based on type, end use, source type and region:
Type Outlook (Revenue, USD Million; 2014 - 2025)
Intrauterine Insemination
Intracervical Insemination
Intravaginal Insemination
Intratubal Insemination
End-use Outlook (Revenue, USD Million; 2014 - 2025)
Fertility Clinics and Others
Home
Source Type Outlook (Revenue, USD Million; 2014 - 2025)
AIH - Husband
AID - Donor
Regional Outlook (Revenue, USD Million; 2014 - 2025)
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
Japan
China
India
Latin America
Brazil
Mexico
Middle East & Africa
South Africa
Explore the BI enabled intuitive market research database,The Grand Library, by Grand View Research, Inc.
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact: Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
SmartCella Holding AB today announces that Dr Ricardo Baptista has been appointed Chief Technology Officer (CTO) and Head of Procella. Ricardo is an experienced Biochemical Engineer with almost 20-years of global experience in the medical...
Every year in Quebec, more than 2,000 young people leave the care of the Director of Youth Protection (DYP) as they approach the age of majority. For youth under the care of the DYP, turning 18 means having to become independent quickly, with little...
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...